BFG
CATX icon

Bleakley Financial Group’s Perspective Therapeutics CATX Stock Holding History

Bleakley Financial Group’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,357
Closed -$39.9K – 1026
2024
Q1 		$39.9K Buy
+3,357
New +$28.6K ﹤0.01% 978

Other funds holding CATX

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bleakley Financial Group's CATX Position: Q2 2024 in Review

Bleakley Financial Group sold out of Perspective Therapeutics (CATX) in Q2 2024, closing a stake of 3,357 shares — an estimated $39.9K sold.

Bleakley Financial Group first reported a position in CATX in Q1 2024 and held it in 1 quarter. The position peaked at $39.9K in Q1 2024. 105 funds tracked by Wall St. Rank hold CATX as of Q2 2024.

  • Bleakley Financial Group reported no remaining Perspective Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bleakley Financial Group sold 3,357 Perspective Therapeutics shares in Q2 2024, an estimated $39.9K.
  • Bleakley Financial Group first reported a position in Perspective Therapeutics in Q1 2024 and held it in 1 quarter.
  • Bleakley Financial Group's Perspective Therapeutics position peaked at $39.9K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2024.

Based on Bleakley Financial Group's 13F filing for Q2 2024, filed 12 Aug 2024.